NFlection Therapeutics
NFlection Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class topical MEK inhibitors for rare dermatological disorders including neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.
- Company typePrivate
- Founded2014
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
NFlection Therapeutics firmographics
Firmographics- Name
- NFlection Therapeutics
- Legal name
- NFlection Therapeutics, Inc.
- Website
- https://nflectionrx.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NFlection Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class topical MEK inhibitors for rare dermatological disorders including neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.
- Ownership category
- akta.pro rank
NFlection Therapeutics industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Dermatology Disorder Therapies (HLAIAIAM)
Keywords
Where NFlection Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NFlection Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through commercialization of novel topical MEK inhibitor therapies for rare dermatological disorders upon successful clinical development and regulatory approval.
Marketing channels1 record
NFlection Therapeutics product offering
Product offeringCore offering
NFlection Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class topical MEK inhibitors for the treatment of rare dermatological disorders driven by aberrant activation of the RAS pathway. Its pipeline targets neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks including keratinocytic epidermal nevi and nevi sebacei. No products are yet commercially available; all candidates are in clinical-stage development.
Differentiator
Problem solved
Functional benefit
Products and services
- Topical MEK Inhibitor Pipeline (NF1 program) Investigational first-in-class topical MEK inhibitors intended for the treatment of neurofibromatosis type 1, including plexiform neurofibromas and other RAS-mediated cutaneous manifestations. Currently in clinical-stage development with no commercial product yet available; intended for NF1 patients and the dermatologists/oncologists who treat them.
- Topical MEK Inhibitor Pipeline (Immunosuppressant-Mediated Squamous Cell Carcinoma program) Investigational first-in-class topical MEK inhibitor candidate targeting cutaneous squamous cell carcinoma arising in immunosuppressed patients (e.g., solid-organ transplant recipients). Aimed at transplant dermatologists and oncodermatologists; currently in clinical-stage development.
- Topical MEK Inhibitor Pipeline (Congenital Birthmarks program) Investigational first-in-class topical MEK inhibitor candidate for the treatment of congenital RAS-mediated birthmarks including keratinocytic epidermal nevi and nevi sebacei. Targeted at pediatric dermatologists and clinical geneticists; currently in clinical-stage development.
Companies that use NFlection Therapeutics
Customer profileSegments3 records
Ideal customer profiles3 records
NFlection Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
NFlection Therapeutics partnerships and signals
Strategic signalScale indicators2 records
NFlection Therapeutics competitors and assessment
Company assessmentDirect peers
- SpringWorks Therapeutics: Commercial-stage rare-disease company that licensed selumetinib (oral MEK inhibitor) from AstraZeneca for NF1-related tumors and other RAS-driven disorders. Closest direct comparator because it competes in the same indication (NF1) using the same molecular target (MEK) but via systemic delivery, making it the benchmark NFlection must beat on safety/convenience.
- Arcutis Biotherapeutics: Late-stage dermatology company developing topical formulations of validated mechanisms (e.g., PDE4, JAK inhibitors) for chronic skin conditions. Highly comparable business model: small/mid-cap biotech focused exclusively on topical dermatology therapeutics with a streamlined development and commercial approach.
- PellePharm (now LEO Pharma): Clinical-stage rare dermatology company that developed patidegib (topical smoothened inhibitor) for Gorlin syndrome and basal cell carcinomas, both RAS-pathway-related. Acquired by LEO Pharma in 2020. Closest historical analog to NFlection's profile: rare-genetic dermatology indication + topical pathway-targeted therapy.
- Aclaris Therapeutics: Clinical-stage biopharmaceutical company developing topical and systemic therapies for immuno-inflammatory and rare dermatology indications. Comparable in stage, scale, and focus on dermatology with kinase-pathway and immunology mechanisms relevant to NFlection's topical MEK pipeline.
- Sol-Gel Technologies: Dermatology company specializing in topical formulations of approved drugs for skin conditions including rare genodermatoses. Shares NFlection's emphasis on topical delivery as a differentiated development strategy within dermatology.
- Dermavant Sciences: Topical dermatology therapeutics company (a Roivant subsidiary) developing novel treatments for inflammatory and rare skin diseases. Comparable in topical drug-development focus and in addressing underserved dermatology indications.
Broad incumbents
- AstraZeneca: Large-cap pharmaceutical company that developed and markets selumetinib (Koselugo), the FDA-approved oral MEK inhibitor for inoperable plexiform neurofibromas in NF1. Competes head-to-head in NF1 dermatology and has vastly greater commercial, regulatory, and clinical resources to expand selumetinib into adjacent indications.
- Alexion (AstraZeneca Rare Disease): Established rare-disease biopharmaceutical company (now part of AstraZeneca) with deep experience commercializing orphan therapies. Relevant benchmark for go-to-market and rare-disease commercialization strategy even though it does not compete directly in topical MEK inhibitors.
Emerging players
- Timber Pharmaceuticals: Small clinical-stage biotech focused on rare dermatologic and metabolic conditions, including genodermatoses. Similar scale and orphan-disease orientation to NFlection, though targeting different mechanisms.
- Castle Creek Biosciences: Late-stage cell-and-gene-therapy company developing treatments for rare dermatologic conditions (e.g., recessive dystrophic epidermolysis bullosa). Operates in the same rare dermatology orphan-disease space as NFlection and represents an alternative development paradigm (cell therapy vs. topical small molecule) for similar indications.
Market position
Customer concentration
NFlection Therapeutics social profiles
Digital presenceNFlection Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NFlection Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
NFlection Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NFlection Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NFlection Therapeutics
What does NFlection Therapeutics do?
NFlection Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class topical MEK inhibitors for the treatment of rare dermatological disorders driven by aberrant activation of the RAS pathway. Its pipeline targets neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks including keratinocytic epidermal nevi and nevi sebacei. No products are yet commercially available; all candidates are in clinical-stage development.
Is NFlection Therapeutics a public or private company?
NFlection Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was NFlection Therapeutics founded?
NFlection Therapeutics was founded in 2014. It employs 11 to 50 people.
Where is NFlection Therapeutics based?
NFlection Therapeutics is headquartered in Boston, United States, in the North America region.
How does NFlection Therapeutics make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are NFlection Therapeutics's main competitors?
Direct peers on record are SpringWorks Therapeutics, Arcutis Biotherapeutics, PellePharm (now LEO Pharma), Aclaris Therapeutics, Sol-Gel Technologies and Dermavant Sciences. Broad incumbents are AstraZeneca and Alexion (AstraZeneca Rare Disease). Emerging players are Timber Pharmaceuticals and Castle Creek Biosciences.
Does NFlection Therapeutics have an API?
No public API is recorded for NFlection Therapeutics.
What industry is NFlection Therapeutics in?
NFlection Therapeutics's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAM, Rare Dermatology Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2836.